Concepedia

Publication | Closed Access

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

DOI

191

Citations

34

References

2012

Year

Kelly E. Dooley, Patrick Sayre, Julie Borland, Elizabeth Purdy, Shuguang Chen, Ivy Song, Amanda Peppercorn, Stephanie Everts, Stephen C. Piscitelli, Charles Flexner
JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

Regimens including twice-daily DTG and RIF or once-daily DTG and RBT may represent a new treatment option for patients who require concomitant treatment of HIV and TB.

References

YearCitations

Page 1